New clinical investigations with selective angiotensin II receptor blocker therapy in diabetes and renal disease

Halting the reduction in glomerular filtration rate (GFR) is the primary aim of any treatment of patients presenting with progressive chronic renal failure, a very common corollary to diabetes. To improve GFR, the high blood pressure (BP) and proteinuria often seen in these patients must both be con...

Full description

Bibliographic Details
Main Author: Luis M Ruilope
Format: Article
Language:English
Published: SAGE Publications 2000-06-01
Series:Journal of the Renin-Angiotensin-Aldosterone System
Online Access:http://jra.sagepub.com/content/1/2_suppl/S29.full.pdf
_version_ 1797284233334489088
author Luis M Ruilope
author_facet Luis M Ruilope
author_sort Luis M Ruilope
collection DOAJ
description Halting the reduction in glomerular filtration rate (GFR) is the primary aim of any treatment of patients presenting with progressive chronic renal failure, a very common corollary to diabetes. To improve GFR, the high blood pressure (BP) and proteinuria often seen in these patients must both be controlled. These symptoms lead not only to progressive loss of renal function, but also to an increase in cardiovascular risk. Use of angiotensin-converting enzyme (ACE) inhibitors in these patients has been reported to control BP and reduce protein excretion and cardiovascular risk. Complete blockade of angiotensin II (Ang II) action with the highly selective Ang II receptor blocker (ARB) valsartan, both as monotherapy and in combination with ACE inhibitors, is well-tolerated and efficacious in patients with renal failure. Unlike ACE inhibition, ARB treatment leads to no initial reduction in GFR, thus valsartan may be a better agent for the control of BP, with greater renal protection.
first_indexed 2024-03-07T17:45:06Z
format Article
id doaj.art-a5fdf50a4cfb4d52aaf7961bee0e1e2d
institution Directory Open Access Journal
issn 1470-3203
1752-8976
language English
last_indexed 2024-03-07T17:45:06Z
publishDate 2000-06-01
publisher SAGE Publications
record_format Article
series Journal of the Renin-Angiotensin-Aldosterone System
spelling doaj.art-a5fdf50a4cfb4d52aaf7961bee0e1e2d2024-03-02T15:18:15ZengSAGE PublicationsJournal of the Renin-Angiotensin-Aldosterone System1470-32031752-89762000-06-0112_supplS29S3110.3317/jraas.2000.05110.3317_jraas.2000.051New clinical investigations with selective angiotensin II receptor blocker therapy in diabetes and renal diseaseLuis M Ruilope0Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain, Luis_M_Ruilope @teleline.esHalting the reduction in glomerular filtration rate (GFR) is the primary aim of any treatment of patients presenting with progressive chronic renal failure, a very common corollary to diabetes. To improve GFR, the high blood pressure (BP) and proteinuria often seen in these patients must both be controlled. These symptoms lead not only to progressive loss of renal function, but also to an increase in cardiovascular risk. Use of angiotensin-converting enzyme (ACE) inhibitors in these patients has been reported to control BP and reduce protein excretion and cardiovascular risk. Complete blockade of angiotensin II (Ang II) action with the highly selective Ang II receptor blocker (ARB) valsartan, both as monotherapy and in combination with ACE inhibitors, is well-tolerated and efficacious in patients with renal failure. Unlike ACE inhibition, ARB treatment leads to no initial reduction in GFR, thus valsartan may be a better agent for the control of BP, with greater renal protection.http://jra.sagepub.com/content/1/2_suppl/S29.full.pdf
spellingShingle Luis M Ruilope
New clinical investigations with selective angiotensin II receptor blocker therapy in diabetes and renal disease
Journal of the Renin-Angiotensin-Aldosterone System
title New clinical investigations with selective angiotensin II receptor blocker therapy in diabetes and renal disease
title_full New clinical investigations with selective angiotensin II receptor blocker therapy in diabetes and renal disease
title_fullStr New clinical investigations with selective angiotensin II receptor blocker therapy in diabetes and renal disease
title_full_unstemmed New clinical investigations with selective angiotensin II receptor blocker therapy in diabetes and renal disease
title_short New clinical investigations with selective angiotensin II receptor blocker therapy in diabetes and renal disease
title_sort new clinical investigations with selective angiotensin ii receptor blocker therapy in diabetes and renal disease
url http://jra.sagepub.com/content/1/2_suppl/S29.full.pdf
work_keys_str_mv AT luismruilope newclinicalinvestigationswithselectiveangiotensiniireceptorblockertherapyindiabetesandrenaldisease